

Date: March 28, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub: Outcome of the Board Meeting held on March 28, 2026 - Allotment of 11,70,000 Warrants Convertible into Equity Shares of the Company on Preferential Basis

Ref: Outcome of the Board Meeting held on January 07, 2026 w.r.t. issue and allotment of warrants by way of preferential issue

Dear Sir/Madam,

In continuation to our earlier intimation dated January 07, 2026 and pursuant to the approval of the Members of the Company dated January 31, 2026 and in accordance with Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI LODR Regulations**”) and in-principle approvals from BSE Limited (“**BSE**”) and National Stock Exchange of India Limited (“**NSE**”) each dated March 13, 2026, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., March 28, 2026 has, inter alia, approved the allotment of 11,70,000 (*Eleven Lakh Seventy Thousand*) warrants convertible into equity shares, each carrying a right to subscribe to 1 (one) Equity Share, at an exercise price of ₹812/- (*Rupees Eight Hundred Twelve Only*) per warrant aggregating to ₹ 95,00,40,000/- (*Rupees Ninety Five Crore Forty Thousand Only*), upon receipt of ₹ 203/- (*Rupees Two Hundred Three Only*) (*being 25% of the issue price per warrant*) amounting to ₹23,75,10,000/- (*Rupees Twenty Three Crores Seventy Five Lakhs Ten Thousand Only*) as warrant subscription price, to the Allotees mentioned in **Annexure I** enclosed herewith.

Further, the warrants allotted on preferential basis shall be subject to such lock-in restriction as prescribed under Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“**SEBI ICDR Regulations**”).

The information in connection with the allotment of securities pursuant to Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as **Annexure II**.

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

The meeting of the Board of Directors of the Company commenced at 11:45 A.M. (IST) and concluded at 12:07 P.M.(IST)

The aforesaid intimation is also being hosted on the website of the Company.

Kindly take on record the same.

Thanking you.


For Senores Pharmaceuticals Limited

Vinay Kumar Mishra

Company Secretary and Compliance Officer

ICSI Membership No.: F11464

Committed to
Global Wellness!



Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Annexure I

Name of the Allottee's	Category	Warrants allotted
Swapnil Jatin Shah	Promoter	1,97,000
Ashokbhai Vijaysinh Barot	Promoter	1,23,000
Renosen Pharmaceuticals Private Limited	Promoter Group	7,39,000
Sangeeta Mukur Barot	Promoter Group	61,500
Viraj Ashokkumar Barot	Promoter Group	49,500
Total		11,70,000

Committed to
Global Wellness!

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Annexure II

DISCLOSURE PURSUANT TO PARAGRAPH 2 OF PART A, SCHEDULE III OF THE SEBI LODR REGULATIONS READ WITH SEBI MASTER CIRCULAR NO. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 DATED JANUARY 30, 2026

Preferential Issue (Disclosure post allotment of Securities):

Sr. No	Particulars	Details of Securities				
1.	Type of Securities	Convertible Warrants carrying a right to subscribe 1 (One) equity share per Warrant				
2.	Type of Issuance	Preferential Issue in accordance with Chapter V of the SEBI ICDR Regulations and other applicable laws.				
3.	Total number of Securities proposed to be issued or the total amount for which the Securities will be issued	11,70,000 (<i>Eleven Lakh Seventy Thousand</i>) warrants convertible into equity shares, each carrying a right to subscribe to 1 (one) Equity Share, at an exercise price of ₹812/- (<i>Rupees Eight Hundred Twelve Only</i>) per warrant aggregating to ₹ 95,00,40,000/- (<i>Rupees Ninety Five Crore Forty Thousand Only</i>) within a maximum period of 18 months from the date of allotment of warrants.				
Disclosure of additional details to the stock exchanges pursuant to the preferential issue of securities:						
Name of the Investors		As per Annexure I				
Post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles),	Investor	Particulars	Pre-Issue shareholding		Post-issue shareholding*	
			No.	%	No.	%
	Swapnil Jatinbhai Shah	Convertible Warrants	35,53,531	7.72	37,50,531	7.94
	Ashokbhai Vijaysinh Barot		34,44,869	7.48	35,67,869	7.56
Renosen Pharmaceuticals Private Limited	27,18,719		5.90	34,57,719	7.32	

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

	Sangeeta Mukur Barot	10,42,955	2.26	11,04,455	2.34
	Viraj Ashokkumar Barot	0	00	49,500	0.10
	Total	1,07,60,074	23.36	1,19,30,074	25.26
	<p><i>* The above post-issue shareholding percentage is calculated, assuming full conversion of Warrants issued pursuant to the Preferential Issue.</i></p> <p>Issue Price: Warrants at an issue price of ₹ 812/- including a premium of ₹802/- per Warrant, of which an amount of ₹ 203/- per warrant has been paid by the Allottees to the Company at the time of allotment of the Warrants and the balance ₹ 609/- per warrant shall be payable to the Company at the time of allotment of the Equity Shares upon exercise of the option to convert the Warrants into Equity Shares.</p>				
	Number of investors	5 (Five)			
	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Each of the Warrants is convertible into 1 (One) Equity Share having face value of ₹10/- (<i>Rupees Ten only</i>) each. The warrants shall be convertible in one or more tranches within a maximum period of 18 months from the date of allotment of warrants.			

For, Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary & Compliance Officer
ICSI Mem. No: F11464

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263